title: Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497).
authors.affiliation: Department of Paediatrics, College of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Molyneux
authors.forename: Blair
authors.initials: B
authors.lastname: Merrick
authors.forename: Farhat L
authors.initials: FL
authors.lastname: Khanim
authors.forename: Kondwani
authors.initials: K
authors.lastname: Banda
authors.forename: Janet A
authors.initials: JA
authors.lastname: Dunn
authors.forename: Gulnaz
authors.initials: G
authors.lastname: Iqbal
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Bunce
authors.forename: Mark T
authors.initials: MT
authors.lastname: Drayson
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001629:Bezafibrate / Q000008:administration & dosage; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D019353:Endemic Diseases; D005260:Female; D006801:Humans; D008295:Malawi / Q000453:epidemiology; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D017258:Medroxyprogesterone Acetate; D001629:Bezafibrate
keywords: Burkitt lymphoma; bezafibrate; efficacy; medroxyprogesterone; toxicity